21 USC Part E
General Provisions Relating to Drugs and Devices
through Pub. L. 116-282, except Pub. L. 116-260
§
360bbb
Expanded access to unapproved therapies and diagnostics
§
360bbb-0
Expanded access policy required for investigational drugs
§
360bbb-0a
Investigational drugs for use by eligible patients
§
360bbb-1
Dispute resolution
§
360bbb-2
Classification of products
§
360bbb-3
Authorization for medical products for use in emergencies
§
360bbb-3a
Emergency use of medical products
§
360bbb-3b
Products held for emergency use
§
360bbb-3c
Expedited development and review of medical products for emergency uses
§
360bbb-4
Countermeasure development, review, and technical assistance
§
360bbb-4a
Priority review to encourage treatments for agents that present national security threats
§
360bbb-4b
Medical countermeasure master files
§
360bbb-5
Critical Path Public-Private Partnerships
§
360bbb-6
Risk communication
§
360bbb-7
Notification
§
360bbb-8
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
§
360bbb-8a
Optimizing global clinical trials
§
360bbb-8b
Use of clinical investigation data from outside the United States
§
360bbb-8c
Patient participation in medical product discussion
§
360bbb-8d
Notification, nondistribution, and recall of controlled substances
Tried the LawStack mobile app?
Join thousands and try LawStack mobile for FREE today.
- Carry the law offline, wherever you go.
- Download CFR, USC, rules, and state law to your mobile device.
